NCT06599502: An ongoing trial by AstraZeneca
This trial is ongoing. It must report results 9 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06599502 |
|---|---|
| Title | A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 18, 2024 |
| Completion date | Oct. 20, 2025 |
| Required reporting date | Oct. 20, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Jan. 8, 2026 |
| Days late | None |